Blog

An Oxford-led study showing that current AI chatbots are not reliably safe or useful for lay people making medical decisions and can mix solid guidance with misleading advice in ways users struggle to interpret.What the study didResearchers from the Oxford Internet Institute and Nuffield Department of Primary Care Health Sciences ran one of the largest user studies to date on AI medical advice, with nearly 1,300 UK participants facing common symptom scenarios (for example, severe headaches, post‑natal fatigue). Participants had to decide what to do (self‑care, see a GP, go to A&amp;E), with some using large language model (LLM) chatbots and others relying on traditional sources such as web search or their own judgement. Main findings Using an LLM did not lead to better health decisions than traditional methods; participants with chatbot access were, on average, no more accurate about what was wrong or what level of care to seek. Chatbot outputs often combined accurate and inaccurate information, so users found it hard to tell which parts to trust, particularly when the model listed multiple possible conditions. Many users did not know which details of their symptoms to share or how to phrase questions, and small changes in wording produced inconsistent, sometimes contradictory answers. Why this matters The study highlights a gap between LLMs’ strong performance on standardised medical knowledge tests and their weaker performance in messy, real‑world interactions with non‑experts. Researchers argue that, despite excitement about AI in healthcare, general‑purpose chatbots are not ready to act as a doctor or a trusted source of medical decision support for patients. Implications and recommendations The authors call for cautious deployment of AI chatbots in health, stressing that current systems can pose risks by giving inconsistent or unsafe advice that may delay appropriate care. They suggest that future work should focus on designing safer, more tightly constrained medical AI tools and better interfaces that guide people on what information to provide and how to interpret responses. About the StudyA new study from the Oxford Internet Institute and the Nuffield Department of Primary Care Health Sciences at the University of Oxford, carried out in partnership with MLCommons and other institutions, reveals a major gap between the promise of large language models (LLMs) and their usefulness for people seeking medical advice. While these models now excel at standardised tests of medical knowledge, they pose risks to real users seeking help with their own medical symptoms.&nbsp;About the Oxford Internet Institute (OII) &nbsp;&nbsp;The Oxford Internet Institute (OII) has been at the forefront of exploring the human impact of emerging technologies for 25 years. As a multidisciplinary research and teaching department, we bring together scholars and students from diverse fields to examine the opportunities and challenges posed by transformative innovations such as artificial intelligence, large language models, machine learning, digital platforms, and autonomous agents.&nbsp;About the University of Oxford &nbsp;Oxford University has been placed number one in the Times Higher Education World University Rankings for the tenth-year running, and number two in the QS World Rankings 2022. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer. Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. &nbsp; &nbsp;Source: <a href="https://www.oii.ox.ac.uk/news-events/new-study-warns-of-risks-in-ai-chatbots-giving-medical-advice/" data-mce-href="https://www.oii.ox.ac.uk/news-events/new-study-warns-of-risks-in-ai-chatbots-giving-medical-advice/">https://www.oii.ox.ac.uk/news-events/new-study-warns-of-risks-in-ai-chatbots-giving-medical-advice/</a>

Oxford Internet Institute study finds 'AI chatbots less helpful than search engines for medical advice'

Nelson Advisors has been referenced in the Journal of Medical Internet Research publication 'Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'.Background: Virtual wards (VWs) are being introduced within the National Health Service (NHS) in England as a new way of delivering care to patients who would otherwise be hospitalized. Using digital technologies, patients can receive acute care, remote monitoring, and treatment in their homes. Integrated care system commissioners are employees involved in the planning of, agreeing to, and monitoring of services within NHS England and have an important role in the adoption and implementation of VWs in clinical practice.Objective: This study aims to develop an understanding of the acceptability and feasibility of adopting and implementing VWs in England from integrated care system commissioners’ perspectives, including the identification of barriers and facilitators to implementation.Methods: Qualitative semistructured interviews were conducted with 20 commissioners employed by NHS England (NHSE) in various geographic regions of England. Thematic analysis was conducted, structured using the framework approach, and informed by the Consolidated Framework for Implementation Research. The COREQ (Consolidated Criteria for Reporting Qualitative Research) guidelines were followed.Source: <a href="https://www.jmir.org/2024/1/e56494/" data-mce-href="https://www.jmir.org/2024/1/e56494/">https://www.jmir.org/2024/1/e56494/</a>References: 9. Lloyd P. Virtual wards: why are they not widely adopted across the US healthcare industry? 2023. Healthcare Technology. URL: https:/​/www.​healthcare.digital/​single-post/​virtual-wards-why-are-they-not-widely-adopted-across-the-us-healthcare-industry [accessed 2024-06-05]

Nelson Advisors referenced in the Journal of Medical Internet Research publication 'Adoption and Implementation of Virtual Wards in England: Qualitative Exploration Study'

Nelson Advisors has been referenced in Springer Nature's &nbsp;'Financing Health and Social Care' publication explorimg questions such as Why do most capitalist economies have socialist health care systems? How can we preserve them? What would Aneurin Bevan think?In this chapter, two separate 2 × 2 analyses are used to examine two issues, these being: the role of the private sector in publicly funded health care systems; and to diagnose and repair the unfairness and inefficiency in adult social care. With respect to the former, by separating out financing (public vs private) from provision (again, public vs private), it can be seen that we might not rule out a role for the private sector in providing care within an NHS-type system. History and evidence support this, the key being that the dominant source of financing, but not necessarily provision, should be public; a form of demand-side socialism. Secondly, by examining social care in terms of its location (either at home or in a home) and the funding source (public vs self-funding), it is shown that there is a strong case for a system of social care financing similar to that for health care, which in the UK, takes the form of the NHS. It is now recognised that health and social care act in parallel. A well-functioning social care system helps prevent people entering the health care system and also facilitates their earlier discharge. The main policy distraction to be assessed here is that reform of the financing of social care (in the UK) is unaffordable. It would cost very little. Indeed, given the growing number of people with Alzheimer in the social care system, there is an inevitability to the case. There is no reason why the market failure arguments applied to caring for people with other medical conditions, and thus in support of an NHS, should not also apply to this group who just happen to be placed in social care.Source: <a href="https://link.springer.com/chapter/10.1007/978-3-031-86769-9_3" data-mce-href="https://link.springer.com/chapter/10.1007/978-3-031-86769-9_3">https://link.springer.com/chapter/10.1007/978-3-031-86769-9_3</a>Source: <a href="https://link.springer.com/book/10.1007/978-3-031-86769-9">https://link.springer.com/book/10.1007/978-3-031-86769-9</a>References14. <a href="https://www.healthcare.digital/single-post/apple-s-healthcare-strategy-build-buy-or-partner-buy-appears-to-be-the-most-likely" data-mce-href="https://www.healthcare.digital/single-post/apple-s-healthcare-strategy-build-buy-or-partner-buy-appears-to-be-the-most-likely">https://www.healthcare.digital/single-post/apple-s-healthcare-strategy-build-buy-or-partner-buy-appears-to-be-the-most-likely</a>.

Nelson Advisors referenced in Springer Nature: Financing Health and Social Care

The European healthcare technology IPO landscape is entering a phase of "Rational Exuberance" in 2026, following a prolonged drought stretching from late 2021 through 2025. The IPO window is reopening—early February 2026 saw biotech companies pull in more than $1 billion from public markets in a single week, including Belgium's Agomab Therapeutics scoring a $200 million NASDAQ listing.&nbsp; &nbsp;&nbsp; However, the European HealthTech IPO market remains highly selective, accessible primarily to companies demonstrating industrial-grade financial metrics, clinical validation, and compliance moats. The trend is decisively toward US listings (the "Delaware Flip") to access deeper liquidity, though European exchanges are reforming aggressively to retain homegrown champions. Premium valuations in 2026–2027 will be reserved exclusively for companies with high gross margins (60–80%), clear paths to profitability, and AI-driven operational efficiency—signalling the definitive end of the "growth at all costs" era.​2027 Outlook: The Maturation Wave - Expected Pipeline &nbsp;&nbsp; By 2027, the European HealthTech IPO pipeline is expected to feature: &nbsp;&nbsp; Sword Health: CEO has publicly guided to a 2028 IPO, but market observers note that secondary liquidity pressures and the performance of peer Hinge Health could accelerate the timeline to 2027. The company is cash-flow positive with a $240 million revenue run rate.​Doctolib: If profitability milestones are achieved, a 2027 listing on Euronext or NASDAQ remains plausible, given its category dominance and $6.4 billion valuation.Neko Health: Following US market entry in 2026, a 2027 listing would capitalise on proven transatlantic demand.​Flo Health: As Europe's first femtech unicorn ($1B+ valuation), Flo is expanding into menopause and B2B employee benefits channels—a 2027 listing would follow further revenue diversification.​Isomorphic Labs: With $600 million raised and Alphabet backing, a 2027 NASDAQ listing is plausible if clinical pipeline candidates emerge from its AI drug discovery platform.Read the report <a href="https://www.healthcare.digital/single-post/european-healthtech-and-medtech-ipo-predictions-2026-and-2027">https://www.healthcare.digital/single-post/european-healthtech-and-medtech-ipo-predictions-2026-and-2027</a>

Nelson Advisors European HealthTech and MedTech IPO Predictions 2026 and 2027

European HealthTech this week is being shaped by regulatory countdowns to the EU AI Act and MDR/IVDR changes, plus continued investor focus on AI‑enabled prevention, data‑rich diagnostics and evidence‑heavy platform plays.Policy and regulationThe EU AI Act is now in force, with high‑risk health AI systems facing core obligations from 2026, including strict data governance, human oversight, documentation and transparency, which directly affects diagnostic, therapeutic and decision‑support tools. Guidance on what will count as “high‑risk” in life sciences and digital health is due by February 2026, clarifying the line between embedded AI in devices and standalone clinical decision support, and therefore shaping launch and funding strategies. In parallel, the Commission’s late‑2025 MDR/IVDR simplification package is driving 2026 discussions, with proposals to streamline notified‑body processes, clarify recertification timelines and improve predictability for EU launches and renewals.​ Data, EHDS and infrastructure 2026 is framed as a preparation year for the European Health Data Space, with growing emphasis on EHDS‑ready data, anonymisation and governance to enable research, AI training and product validation. EU‑level programmes such as Horizon Europe and HADEA‑managed health and digital calls are releasing non‑dilutive capital into digital infrastructure, including projects for real‑time patient monitoring, remote surgical support, faster clinical data access and cybersecurity hardening in hospitals. These funding streams are explicitly backing cross‑border platforms built around EHDS‑style data flows, setting up potential future roll‑up nuclei in digital health infrastructure.​ Funding and company moves Preventive health remains one of the most funded HealthTech themes in Europe, with strong investor interest in AI‑enabled early detection, wellness/clinical hybrids and longitudinal engagement platforms. A recent example highlighted this week is Zurich‑based Ahead Health, which raised around 6 million USD to expand an AI‑native “personal health operating system” model across Switzerland, Germany and further EU markets.​ MedTech funding continues to tilt toward AMR diagnostics, cardiology and robotics, illustrated by rounds such as the €24 million raise for Dutch AMR diagnostics player ShanX Medtech, which features prominently in early‑2026 deal lists.​ Market and investor sentiment The broader 2026 venture outlook describes European HealthTech and MedTech as entering an “industrial maturity” phase: less speculative fragmentation, more focus on profitable efficiency, regulatory resilience and defensible data advantages. The AI Act’s treatment of medical AI as high‑risk has become a binary filter for capital, effectively rendering “black box” clinical AI models uninvestable in Europe and pushing funds toward explainable “glass box” architectures with privacy‑by‑design. Combined AI, MDR/IVDR and EUDAMED changes are expected to concentrate M&amp;A on fewer, higher‑value assets in robotics, neuro, advanced diagnostics and workflow‑automation, particularly where regulatory narratives and data moats are strongest. Events and ecosystem signals Athens Digital Health Week 2026 and other pan‑European conferences announced for February and later in the year are positioning themselves around trusted, evidence‑led digital health and AI in care delivery, reflecting the regulatory and funding themes above. Ecosystem watchers such as Galen Growth are flagging 2026 as a “real test” year in Europe, where exits and industrialisation of prior vintages, rather than headline round sizes, will determine whether the 2025 digital health funding boom translates into durable value.​To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;European MedTech this week is being driven by sharper MDR/IVDR proposals in Brussels, a visible tightening of software and cybersecurity rules, and a set of funding and certification milestones that reinforce the “industrial maturity” narrative for devices and diagnostics.Regulation: MDR/IVDR and software tightening The European Commission’s late‑2025 MDR/IVDR amendment package is now the main reference point in 2026 discussions, with proposals to streamline notified‑body oversight, clarify recertification timelines and improve predictability for launches and renewals.​ Fresh analysis this week highlights draft revisions that sharpen requirements for digital MedTech: clearer rules for software classification, cybersecurity obligations, and incident‑reporting, all of which raise the bar for connected devices and SaMD while promising more consistent interpretation across member states.​ EUDAMED’s staged rollout and looming 2026 transparency deadlines continue to influence manufacturers’ portfolio planning and due‑diligence narratives, reinforcing the shift from regulatory ambiguity to “tight but knowable” compliance. Funding and dealflow signals The latest European MedTech and digital health brief for the week of 2–8 February showcases a mix of growth and earlier‑stage capital, underlining that targeted theme‑based funding is still available even as the market cools overall.​ Highlights include NuVision Biotherapies, a Nottingham‑based ocular wound‑healing spin‑out, raising about £4.8 million (roughly €5.7 million) to expand amniotic‑membrane therapies into 12 new countries, and Gardia in Germany securing €8.5 million Series A for senior‑care fall‑detection wearables across DACH.​ AI‑enabled clinical‑trial tooling also features prominently via Biorce’s approximately €48.6 million Series A, signalling investor appetite for infrastructure that reduces protocol‑amendment costs and accelerates study execution for MedTech and pharma alike.​ Market structure and industrialisation theme Commentators portray 2026 as the “Great Rationalisation” or “industrial maturity” phase for European HealthTech and MedTech, with focus rotating from top‑line growth to profitable efficiency, regulatory robustness and data‑advantaged device platforms. This environment is expected to concentrate M&amp;A and late‑stage capital on fewer assets in robotics, neuro‑interventions, cardiology and advanced diagnostics, particularly where companies can demonstrate clean MDR/IVDR pathways, EUDAMED‑ready documentation and explainable AI where software is involved. Investor commentary stresses that “black‑box” algorithms embedded in devices will increasingly struggle in Europe under both the AI Act and revised MDR software rules, pushing MedTech strategies toward interpretable, auditable models and strong post‑market surveillance. Notable ecosystem moves The weekly brief also flags MDR certification of STIMULAN Rapid Cure as the first calcium‑matrix carrier approved for combined‑antibiotic use in bone and soft tissue, a useful proof‑point that complex new materials can still clear the MDR bar with the right evidence strategy.​ Leadership moves such as the new CEO appointment at imaging specialist Guerbet are framed around accelerating execution in contrast media, interventional solutions and AI integration, reinforcing that incumbents are doubling down on data‑rich product lines rather than broad diversification.​ An Invest Europe / EIF report cited in the same brief notes that while capital is consolidating, an increasing share of late‑stage European digital health and MedTech rounds feature US‑led syndicates, underlining ongoing transatlantic influence on valuation and exit expectations.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 13th February 2026

The global healthcare ecosystem has entered 2026 at a profound inflection point. After a five year period characterised by unprecedented capital infusion and a "valuation euphoria" surrounding artificial intelligence, the industry is currently navigating what economists and clinical experts describe as the "Coming Clinical Correction".&nbsp; &nbsp;&nbsp; While AI investment in healthcare reached a staggering $1.4 Billion in 2025, outpacing other industrial sectors by a factor of 2.2, the divergence between technological promise and measurable clinical outcomes has created a classic bubble environment.&nbsp; This report provides an analysis of the primary mechanisms through which this bubble is decompressing in 2026, shifting the market from speculative hype to a disciplined, evidence based paradigm. &nbsp;<a href="https://www.healthcare.digital/single-post/healthcare-ai-bubble-bursting-2026-risks">https://www.healthcare.digital/single-post/healthcare-ai-bubble-bursting-2026-risks</a>The transition from "AI euphoria" to "investor discipline" is moving the industry toward a "Health Tech 2.0" phase where trust is earned through clinical validation, interoperable design, and ethical transparency. For healthcare organisations, the path forward in 2026 requires vendor stress testing, rigorous internal governance, and a refusal to allow technological deployment to outpace clinical evidence.&nbsp; &nbsp;&nbsp; The organisations that successfully navigate this reckoning will emerge with AI systems that are no longer "shiny pilots" but governed, safe, and everyday tools of modern medicine.Read the report here <a href="https://www.healthcare.digital/single-post/healthcare-ai-bubble-bursting-2026-risks">https://www.healthcare.digital/single-post/healthcare-ai-bubble-bursting-2026-risks</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Oxford Internet Institute study finds 'AI chatbots less h...

Nelson Advisors referenced in the Journal of Medical Inte...

Nelson Advisors referenced in Springer Nature: Financing ...

Nelson Advisors European HealthTech and MedTech IPO Predi...

This Week in European MedTech and HealthTech: 13th Februa...

The 2026 Healthcare AI Reckoning: Analysis of the Clinica...